1304316
doi
10.5281/zenodo.1304316
oai:zenodo.org:1304316
user-sgc-opennotebook
user-openlabnotebooks
Vedadi, Masoud
Structural Genomics Consortium/University of Toronto
The process of HDAC11 Assay Development: Effect of reducing agent
Abbey, Megha
Structural Genomics Consortium/University of Toronto
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
HDAC11
histone deacetylase
histone deacetylase 11
enzyme activity
assay optimization
<p>An effect of adding reducing agent on the HDAC11 activity was monitored.</p>
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Zenodo
2018-07-03
info:eu-repo/semantics/other
1304315
user-sgc-opennotebook
user-openlabnotebooks
1579893830.009142
94115
md5:3ad64d7c8ef149aba97bd4539c1f9f8f
https://zenodo.org/records/1304316/files/3july2018-HDAC11-reducing agent.pdf
public
10.5281/zenodo.1304315
isVersionOf
doi